Legal Proceedings
−Removed: From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities.
−Removed: Although the results of litigation and claims cannot be predicted with certainty, we do not believe we are party to any other claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be
−Removed: reasonably expected to have a material adverse effect on our business.
−Removed: Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
−Removed: Our material risk factors are disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange
−Removed: Commission on March 1, 2021.
+Added: From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.
+Added: Although the results of litigation and claims
+Added: cannot be predicted with certainty, the Company does not believe it is party to any other claim or litigation the outcome of which, if determined adversely to the Company, would individually or in the aggregate be reasonably expected to have a
+Added: material adverse effect on its business.
+Added: Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors.
+Added: Our material risk factors are disclosed in Item 1A of our 2021 Form 10-K.
There have been no material changes from the risk factors previously disclosed in such filing.
4 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.